Homepage Top Section2

Lilly signed the definitive agreement to acquire Versanis Bio in July this year. At the time of the deal announcement, its terms specified that shareholders of Versanis were

Stockholders of Chinook will receive $40.00 in cash per share, a total of $3.2bn, from Novartis. Upon achieving certain regulatory milestones, they will further receive $4.00 in cash

In June this year, the therapy, in combination with Genentech’s Tecentriq received FDA fast track designation (FTD) for the treatment of extensive-stage small cell lung cancer (ES-SCLC) patients.

The expansion involved addition of one 50L, two 200L, and two 1,000L suspension single-use bioreactors. It also offers the flexibility to accommodate up to four iCellis500 adherent single-use

The agreement for VAZKEPA capsules comes after approval from Israel’s Ministry of Health (MOH) Pharmaceuticals Division. The approval of these capsules has been granted for reducing cardiovascular events

The subsidiary, Daiichi Sankyo RD Novare (RD Novare), with nearly 400 employees was initially named as Daiichi Sankyo RD Associe in 2006 and was changed to the current

Said to be the first and only oral, once-a-day, 14-day treatment, ZURZUVAE can provide quick improvements in depressive symptoms for women with PPD. Shortly after scheduling as a

As per the terms of the exclusive worldwide agreement, Agios will acquire the rights to develop and market Alnylam’s preclinical candidate that targets TMPRSS6, a key driver of

The company received the patent from the European Patent Office. The drug is being assessed in the ongoing Phase III programme CONCLUDE for treating patients with moderate to